VALENCIA, Calif. , April 16 /PRNewswire-FirstCall/ -- MannKind Corporation
(Nasdaq: MNKD) today announced that
Mr. Pfeffer served as Chief Financial Officer and Senior Vice President of
Finance and Administration of VaxGen, Inc. from March 2006 until April 2008 ,
with responsibility for finance, tax, treasury, human resources, IT,
purchasing and facilities functions. Prior to VaxGen, Mr. Pfeffer served as
CFO of Cell Genesys, Inc. During his nine-year tenure at Cell Genesys, Mr.
Pfeffer served as Director of Finance before being named CFO in 1998. Prior
to that, Mr. Pfeffer served in a variety of financial management positions at
other companies, including roles as Corporate Controller, Manager of Internal
Audit and Manager of Financial Reporting. Mr. Pfeffer began his career at
Price Waterhouse. Mr. Pfeffer is a member of the board of directors of
Genelabs Technologies, Inc. He also serves on boards and advisory committees
of Financial Executives International, the Biotechnology Industry Organization
and the American Institute of Certified Public Accountants. Mr. Pfeffer
graduated from the
'Matt is a seasoned and knowledgeable Chief Financial Officer with over
25 years of demonstrated financial management experience. We know that he
will play a significant role on MannKind's executive leadership team as we
continue to develop our pipeline of diabetes and oncology products,' said
About MannKind Corporation
MannKind Corporation (Nasdaq: MNKD) focuses on the discovery, development and commercialization of therapeutic products for diseases such as diabetes and cancer. Its lead product, the Technosphere(R) Insulin System, is currently in phase 3 clinical trials in the United States , Europe and Latin America to study its safety and efficacy in the treatment of diabetes. For more information on MannKind Corporation and its technology, visit http://www.mannkindcorp.com.
SOURCE MannKind Corporation
